SalaryGuide
AboutPricingFor Employers

Marketing jobs

5 marketing jobs

Lilly logo
7 days ago

Associate Director, Oncology Communications

Lilly

Indianapolis, IN (Remote)Full time$128K/yr – $187K/yr
GoodPower logo
4 weeks ago

Impact Communications Associate Director, Communications

GoodPower

USA (Remote)Full time$100K/yr – $120K/yr
The George Washington University logo
4 weeks ago

Communications Associate Director

The George Washington University

District of Columbia, USA (Remote)Full time$74K/yr – $102K/yr
Nickerson logo
3 months ago

Associate Director, PR & Communications

Nickerson

Boston, MA (Remote)Full time
Right To The City Alliance logo
4 months ago

Associate Director of Communications

Right To The City Alliance

New York, USA (Remote)Full time

All marketing roles in the US with a remote work arrangement

Get alerts for this search

All marketing roles in the US with a remote work arrangement

Get alerts for this search

5 jobs
Lilly logo

Associate Director, Oncology Communications

Lilly

Indianapolis, IN (Remote)

$128K/yr - $187K/yrIn-houseFull-timeMid level5+ years exp.
7 days ago
GoodPower logo

Impact Communications Associate Director, Communications

GoodPower

USA (Remote)

$100K/yr - $120K/yrIn-houseFull-timeDirector/executive8+ years exp.
4 weeks ago
The George Washington University logo

Communications Associate Director

The George Washington University

District of Columbia, USA (Remote)

$74K/yr - $102K/yrIn-houseFull-timeSenior level2+ years exp.
4 weeks ago
Nickerson logo

Associate Director, PR & Communications

Nickerson

Boston, MA (Remote)

AgencyFull-timeSenior level6+ years exp.
3 months ago
Right To The City Alliance logo

Associate Director of Communications

Right To The City Alliance

New York, USA (Remote)

In-houseFull-timeMid level7+ years exp.
4 months ago
Lilly logo
Lilly

Associate Director, Oncology Communications

Indianapolis, IN (Remote)

$128K/yr – $187K/yrMid Level5+ years expFull time

Posted 7 days ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Lead the development and execution of communications plans for priority products and pipeline programs, crafting press materials, messages, and Q&As while measuring impact and coordinating with Legal, Regulatory, and cross-functional partners.

  • Own branded and unbranded campaigns across multiple channels
  • Drive content development and analytics-driven optimization

Job Description

Responsibilities

  • Support the development and execution of communications plans for priority products and pipeline programs, including data readouts and disclosures, regulatory achievements and branded and unbranded communications strategies
  • Develop content including press materials, key messages, standby statements, Q&A documents, fact sheets, executive talking points, and internal communications
  • Implement effective branded and unbranded communications tactics to reach priority audiences using a variety of channels
  • Stay current with the competitive landscape and external environment, flagging emerging issues and opportunities
  • Flex across products, pipeline programs and other projects, as needed
  • Partner with agency resources and external vendors to implement communications plans
  • Use analytics and measurement to assess communications impact and recommend improvements
  • Collaborate with cross-functional partners including Legal, Regulatory, Medical Affairs, IR, and more

Requirements

  • Bachelor's degree
  • 5+ years of communications experience in pharmaceutical, biotech, or healthcare environments
  • Qualified applicants must be authorized to work in the United States on a full-time basis. Lilly will not provide support for or sponsor work authorization or visas for this role, including but not limited to F-1 CPT, F-1 OPT, F-1 STEM OPT, J-1, H-1B, TN, O-1, E-3, H-1B1, or L-1.

Preferred

  • Experience with scientific or clinical data communications
  • Strong written and verbal communication skills
  • Experience in the oncology space
  • Demonstrated ability to translate complex scientific information into clear, compelling content for diverse audiences
  • Strong organizational skills with the ability to manage multiple workstreams and shift priorities rapidly
  • Collaborative mindset while operating across projects and functional boundaries
  • Proactive, solutions-oriented approach
  • Outstanding attention to detail
  • Experience working in a matrixed organization with sophisticated collaborator dynamics
  • Deep understanding of traditional and emerging communication approaches and channels

Benefits

  • Lilly offers a comprehensive benefit program to eligible employees, including eligibility to participate in a company-sponsored 401(k); pension; vacation benefits; eligibility for medical, dental, vision and prescription drug benefits; flexible benefits (e.g., healthcare and/or dependent day care flexible spending accounts); life insurance and death benefits; certain time off and leave of absence benefits; and well-being benefits (e.g., employee assistance program, fitness benefits, and employee clubs and activities).
Lilly logo

Lilly

🚀 Lilly - La Révolution du Recrutement Automatisé ! 🚀Simplifiez votre sourcing, boostez votre productivité et trouvez les meilleurs talents en un temps record ! 🔍Avec Lilly, vous pouvez : 💡 Automatiser la recherche et la sélection des meilleurs candidats. ⚡ Lancer votre sourcing en moins de 60 secondes. 🎯 Identifier les talents parfaits grâce à une technologie de pointe en IA. 💬 Envoyer des messages personnalisés et engageants automatiquement. 📈 Optimisez vos recrutements et réduisez le temps passé à chercher des candidats.L'essai est 100% gratuit et vous permet de découvrir à quel point votre recrutement peut être plus rapide, intelligent, et efficace.Vous êtes une agence, une start-up, un ESN ou une entreprise en croissance ? Lilly est faite pour vous !💥 Rejoignez la révolution du recrutement dès maintenant ! 💥

1 employees
lilly-recruiter.com

Headcount Trend

Current headcount: ~1

Marketing Team

Median Tenure
29.6 years
Marketing Roles Posted (Last 30 Days)
6

People

Founders / CEO

Lilly KipLee
Lilly KipLee
CEO and Founder
At the company for 10 years

HR / Recruitment

Ryan Burke
Ryan Burke
Talent Acquisition - HR Global Recruiting & Staffing
At the company for 35 years 7 months

Recent News

Eli Lilly to build $6 billion Alabama plant as part of US manufacturing push
Dec 10, 2025 • Reuters
Eli Lilly announces $6 billion pharmaceutical manufacturing investment in Huntsville
Dec 9, 2025 • City of Huntsville (.gov)
Governor Ivey Announces Pharmaceutical Giant Lilly Plans $6 Billion Advanced Manufacturing Plant in Huntsville
Dec 9, 2025 • Alabama Governor's Office (.gov)
Eli Lilly Plans $6 Billion Investment, 450 Jobs In Huntsville
Dec 9, 2025 • Huntsville Business Journal
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
Dec 9, 2025 • Eli Lilly and Company
Eli Lilly to build $6 billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs
Dec 9, 2025 • CNBC
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
Dec 9, 2025 • PR Newswire
Lilly and IU to expand access to clinical trials and latest innovative treatments for Hoosiers
Dec 3, 2025 • News at IU
Lilly lowers the price of Zepbound® (tirzepatide) single-dose vials | Eli Lilly and Company
Dec 1, 2025 • Eli Lilly and Company
Eli Lilly unveils new direct-to-employer model for weight loss drugs
Nov 21, 2025 • Fierce Healthcare
Lilly becomes first drugmaker to hit $1 trillion valuation on weight-loss demand
Nov 21, 2025 • Reuters
Lilly announces plans to open Lilly Gateway Labs site in Philadelphia
Nov 19, 2025 • PR Newswire
Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans
Nov 6, 2025 • Eli Lilly and Company
White House announces deals with Eli Lilly, Novo Nordisk to lower drug costs
Nov 6, 2025 • American Hospital Association
Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide | Eli Lilly and Company
Nov 3, 2025 • Eli Lilly and Company
Eli Lilly’s weight loss and diabetes drug tops Keytruda as world’s best-selling medicine
Oct 30, 2025 • statnews.com
Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance
Oct 30, 2025 • Eli Lilly and Company
Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States | Eli Lilly and Company
Oct 29, 2025 • Eli Lilly and Company
Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States
Oct 29, 2025 • PR Newswire
Eli Lilly to invest $1.2 billion in Puerto Rico as part of US manufacturing push
Oct 29, 2025 • Reuters
Lilly partners with NVIDIA to build the industry's most powerful AI supercomputer, supercharging medicine discovery and delivery for patients | Eli Lilly and Company
Oct 28, 2025 • Eli Lilly and Company
Eli Lilly, NVIDIA team up to build pharma’s biggest AI supercomputer
Oct 28, 2025 • statnews.com
Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial | Eli Lilly and Company
Oct 24, 2025 • Eli Lilly and Company
Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes | Eli Lilly and Company
Oct 15, 2025 • Eli Lilly and Company
Eli Lilly’s strategy in motion: Beyond diabetes and obesity
Sep 24, 2025 • Labiotech.eu
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas
Sep 23, 2025 • PR Newswire
Eli Lilly to make weight-loss pill in new $6.5 billion Texas plant
Sep 23, 2025 • Reuters
Governor Abbott Announces New Eli Lilly Manufacturing Investment In Harris County
Sep 23, 2025 • Office of the Texas Governor (.gov)
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas
Sep 23, 2025 • Eli Lilly and Company
Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine
Sep 16, 2025 • Eli Lilly and Company
Lilly unveils 1st of 4 new US manufacturing sites with $5B Virginia API plant
Sep 16, 2025 • Fierce Pharma
Drug manufacturer Eli Lilly to build plant in Goochland, create 650 permanent jobs
Sep 16, 2025 • Virginia Mercury
Lilly trial shows weight loss with experimental pill flattens over time
Sep 16, 2025 • Reuters
Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment
Sep 9, 2025 • Eli Lilly and Company
Eli Lilly temporarily halts UK shipments of weight-loss drug Mounjaro
Aug 27, 2025 • Reuters
Lilly's Verzenio® (abemaciclib) increases overall survival in HR+, HER2-, high-risk early breast cancer with two years of therapy | Eli Lilly and Company
Aug 27, 2025 • Eli Lilly and Company
Anne White to Retire as Executive Vice President and President, Lilly Neuroscience
Aug 20, 2025 • Eli Lilly and Company
Lilly shares fall as obesity pill misses expectations in key trial
Aug 7, 2025 • BioPharma Dive
Lilly raises full-year earnings forecasts on surging demand for weight-loss drug
Aug 7, 2025 • Reuters
Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity | Eli Lilly and Company
Aug 7, 2025 • Eli Lilly and Company
Wisconsin offering up to $100M in development incentives to Eli Lilly's Kenosha County project
Aug 5, 2025 • WPR
Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease
Jul 31, 2025 • Eli Lilly and Company
Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease
Jul 30, 2025 • Eli Lilly and Company
Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica (ibrutinib) in CLL/SLL
Jul 29, 2025 • Eli Lilly and Company
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk | Eli Lilly and Company
Jul 25, 2025 • Eli Lilly and Company
FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease | Eli Lilly and Company
Jul 9, 2025 • Eli Lilly and Company
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials | Eli Lilly and Company
Jun 22, 2025 • Eli Lilly and Company
Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine
Jun 21, 2025 • Eli Lilly and Company
Lilly partners with Camurus in search of a long-lasting obesity drug
Jun 4, 2025 • BioPharma Dive
Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting
Jun 2, 2025 • Eli Lilly and Company
Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics | Eli Lilly and Company
May 27, 2025 • Eli Lilly and Company
Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation
May 9, 2025 • Purdue University
Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
May 1, 2025 • Eli Lilly and Company
Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial
Apr 17, 2025 • Eli Lilly and Company
Experimental Lilly drug cuts genetic heart disease risk factor by 94% in trial
Mar 30, 2025 • Reuters
Lilly’s statement about the CHMP opinion issued for donanemab | Eli Lilly and Company
Mar 28, 2025 • Eli Lilly and Company
Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion | Eli Lilly and Company
Feb 26, 2025 • Eli Lilly and Company
Lilly expands US manufacturing build-out with $50B target
Feb 26, 2025 • BioPharma Dive
Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients
Feb 25, 2025 • Eli Lilly and Company
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
Jan 15, 2025 • Eli Lilly and Company
Announcement: Andreessen Horowitz Partners with Lilly to Launch First-of-Its-Kind Biotech Ecosystem Fund
Jan 14, 2025 • Andreessen Horowitz
Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast
Jan 14, 2025 • Reuters
Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program | Eli Lilly and Company
Jan 13, 2025 • Eli Lilly and Company